Literature DB >> 2024291

FLAP: a novel drug target for inhibiting the synthesis of leukotrienes.

A W Ford-Hutchinson1.   

Abstract

FLAP (5-lipoxygenase-activating protein) is a novel 18 kDa membrane protein that together with 5-lipoxygenase is required for cellular leukotriene biosynthesis. Tony Ford-Hutchinson describes a novel class of leukotriene biosynthesis inhibitor, exemplified by MK0886, that can bind to FLAP with high affinity, prevent the activation of 5-lipoxygenase by preventing the translocation of the enzyme from the cytosol to the membrane and inhibit leukotriene production. The term 'translocation inhibitors' may be used for inhibitors such as MK0886 and may represent a new class of drug.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024291     DOI: 10.1016/0165-6147(91)90500-r

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  21 in total

Review 1.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

Review 2.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

3.  An anti-platelet agent, OPC-29030, inhibits translocation of 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid production in human platelets.

Authors:  Y Ozeki; Y Nagamura; H Ito; F Unemi; Y Kimura; T Igawa; J i Kambayashi; Y Takahashi; T Yoshimoto
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Peripheral blood neutrophil leukotriene B4 release and migration in rheumatoid arthritis.

Authors:  H Kankaanranta; E Moilanen; T Tuomiranta; M Korpela; U Yli-Kerttula; H Isomäki; H Vapaatalo
Journal:  Inflammation       Date:  1996-10       Impact factor: 4.092

Review 5.  New perspectives on basic mechanisms in lung disease. 3. Drug intervention in asthma: present and future.

Authors:  V A Alabaster; B A Moore
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

Review 6.  Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions.

Authors:  A W Ford-Hutchinson
Journal:  Springer Semin Immunopathol       Date:  1993

Review 7.  Rationally designed multitarget agents against inflammation and pain.

Authors:  S H Hwang; A T Wecksler; K Wagner; B D Hammock
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Blockade of endogenous leukotrienes exacerbates pulmonary histoplasmosis.

Authors:  Alexandra I Medeiros; Anderson Sá-Nunes; Edson G Soares; Camila M Peres; Célio L Silva; Lúcia H Faccioli
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis.

Authors:  R Fruchtmann; K H Mohrs; A Hatzelmann; S Raddatz; B Fugmann; B Junge; H Horstmann; R Müller-Peddinghaus
Journal:  Agents Actions       Date:  1993-03

10.  Down-regulation of vinculin upon MK886-induced apoptosis in LN18 glioblastoma cells.

Authors:  A M Magro; A D Magro; C Cunningham; M R Miller
Journal:  Neoplasma       Date:  2007       Impact factor: 2.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.